" was reported in Texas. The New York Times (4/22, Al, Weiland, LaFraniere, 20.6M) quotes FDA Center for Biologics Evaluation and Research Director Peter Marks as saying, "We know that it's not a good thing to leave the pause going for any longer than it absolutely has to go for. ... Once, essentially, the